AMENDMENT U.S. APPLN. NO. 09/869,122

O64929

lesions a pharmaceutically effective amount of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof, and a pharmaceutically acceptable carrier or diluent.

- 15. The method of both inhibiting proliferation of myeloma cells and suppressing bone resorption according to claim 14, wherein the pharmaceutically effective amount of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof is 1 to 20 mg per day.
- 16. The method of both inhibiting proliferation of myeloma cells and suppressing bone resorption according to claim 14, wherein the pharmaceutically effective amount of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof is 3 to 10 mg per day.
- 17. The method of both inhibiting proliferation of myeloma cells and suppressing bone resorption according to any one of claims 14-16, wherein the pharmaceutically effective amount of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof is administered orally.
- 18. A method of inhibiting proliferation of myeloma cells, comprising administering to a patient suffering from multiple myeloma a pharmaceutically effective amount of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof, and a pharmaceutically acceptable carrier or diluent.
- 19. The method of inhibiting proliferation of myeloma cells according to claim 18, wherein the pharmaceutically effective amount of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof is 1 to 20 mg per day.

Conta

- 20. The method of inhibiting proliferation of myeloma cells according to claim 18, wherein the pharmaceutically effective amount of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof is 3 to 10 mg per day.
- 21. The method of inhibiting proliferation of myeloma cells according to any one of claims 18-20, wherein the pharmaceutically effective amount of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof is administered orally.